Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.
Investors 1
Mentions in press and media 1
| Date | Title | Description |
| 11.12.2024 | Eikonizo Therapeutics Receives Equity Investment From Novo Nordisk | Eikonizo Therapeutics, a Cambridge, MA-based biopharmaceutical company dedicated to developing disease-modifying therapies, received an investment from Novo Nordisk through its Science2Medicine iNNvest initiative.
The amount of the deal was... |
Reviews 0
